Dr. Reddy's and Nestlé Health Science Launch Celevida GLP+ to Address Protein Deficiency in GLP-1 Patients

As GLP-1 receptor agonist prescriptions scale across metabolic disease management, Dr. Reddy's Laboratories and Nestlé Health Science have moved to close a documented nutritional gap in that patient population, co-launching Celevida GLP+ in India. The product targets the protein insufficiency that clinical evidence associates with GLP-1 therapy-induced appetite suppression and accelerated lean mass loss.

Clinical guidelines and expert consensus currently recommend 1.2–1.5 g/kg/day protein intake during GLP-1 therapy to preserve skeletal muscle. That threshold is difficult to meet when caloric intake drops sharply, a pharmacodynamic consequence of the drug class rather than patient non-compliance. Celevida GLP+ is positioned as a medical nutrition solution designed to meet that specific intake target within a reduced-volume format.

For manufacturers and formulators tracking adjacent development pipelines, the partnership illustrates a structural shift: GLP-1 adoption is generating downstream demand for condition-specific nutritional products that sit at the intersection of pharmaceutical and nutraceutical regulatory frameworks. In India, that space involves coordination across FSSAI standards for medical foods and CDSCO oversight where therapeutic claims are involved, adding compliance complexity that pure nutraceutical players are less equipped to navigate.

The Dr. Reddy's and Nestlé Health Science collaboration brings together an established pharmaceutical distribution network and a medical nutrition formulation capability, a pairing that reflects how GLP-1's commercial footprint is reshaping business development calculus for mid-to-large pharma organizations. QA and regulatory leads at companies evaluating similar adjacencies will need to map product classification early, since the boundary between a medical nutrition product and a drug-adjacent therapeutic claim carries distinct dossier and labeling obligations under Indian and ICH-aligned frameworks.

Celevida GLP+'s market entry will serve as an early indicator of whether condition-linked medical nutrition products can achieve formulary-level uptake alongside GLP-1 prescriptions, or whether physician adoption requires dedicated clinical evidence packages beyond the existing protein-intake consensus.

Source: Media4Growth via Indian Pharma Post, 6 May 2026.